No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children.

It has been suggested that lamotrigine (LTG) may enhance the toxicity of carbamazepine (CBZ) by increasing the concentration of the active metabolite carbamazepine-10,11-epoxide (CBZ-E) in adult patients. The authors investigated this hypothesis in an add-on study in 11 children and 3 adolescents, aged 6-22 years, who had been treated for more than 1 year with CBZ in monotherapy or with CBZ in combination with one or two other antiepileptic drugs. The LTG dosage was increased step by step until clinical response or side effects were observed. The plasma concentrations of LTG, CBZ, and CBZ-E were monitored during steady state conditions before and after the addition of LTG. It was found that LTG had no effect on mean CBZ concentrations and that it decreased rather than increased the mean plasma concentration of CBZ-E from 6.4 +/- 2.6 to 4.9 +/- 2.4 mumol/l (mean +/- SD, n = 14, P = 0.019). Observed side effects were diplopia in two children, agitation in two, and increased number of seizures in one. None of these five patients had unusually high CBZ-E levels when the side effect developed. It is concluded that addition of lamotrigine in children treated with carbamazepine children does not result in a pharmacokinetic interaction with a toxic accumulation of carbamazepine-10,11-epoxide.